A novel therapeutic approach utilizing modified mRNA technology has demonstrated promising early results in a small cohort of patients diagnosed with the rare and aggressive Fanconi anemia subtype FA-D, according to research published February 12, 2026, in the Novel England Journal of Medicine.
The study, led by researchers at Boston Children’s Hospital, details the utilize of mRNA designed to temporarily restore functional FANCD1 protein expression in bone marrow cells. Fanconi anemia is a genetic disorder characterized by bone marrow failure and an increased risk of leukemia. The FA-D subtype, representing approximately 20% of cases, results from mutations in the FANCD1 gene. Current treatment options are limited to hematopoietic stem cell transplantation, which carries significant risks.
The initial trial involved six patients, aged 10 to 22, with confirmed FA-D. Patients received escalating doses of the modified mRNA via intravenous infusion. Researchers monitored blood cell counts, bone marrow cellularity, and levels of FANCD1 protein expression. Preliminary data indicate a dose-dependent increase in FANCD1 protein levels in bone marrow cells of treated patients. Three patients showed a sustained improvement in peripheral blood counts, specifically an increase in neutrophils and platelets, suggesting a degree of bone marrow recovery.
Whereas the observed improvements are encouraging, researchers emphasize that the study is in its early stages. The duration of FANCD1 protein expression following mRNA infusion appears to be transient, necessitating repeated administrations. Long-term efficacy and safety remain unknown. The New England Journal of Medicine published initial findings from similar research in August 2025, and October 2, 2025, further detailing mRNA therapeutic approaches. These earlier publications focused on the challenges of mRNA delivery and immune response modulation, areas the current study also addresses through modifications to the mRNA structure and the use of immunosuppressive agents.
The research team is currently recruiting patients for a Phase 2 clinical trial, which will evaluate the optimal dosing regimen and assess the long-term effects of the mRNA therapy. The trial will also investigate biomarkers to predict treatment response and monitor for potential adverse events. The Food and Drug Administration has granted the program Fast Track designation, expediting the review process.
As of February 18, 2026, the National Institutes of Health has not issued a formal statement regarding the findings, and representatives from the Fanconi Anemia Research Fund declined to comment beyond acknowledging the publication of the study. Further data from the ongoing Phase 2 trial are expected to be presented at the annual meeting of the American Society of Hematology in December 2026.
